کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
6002778 1182980 2011 7 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
A common standard is inappropriate for determining the potency of ultra low molecular weight heparins such as semuloparin and bemiparin
موضوعات مرتبط
علوم پزشکی و سلامت پزشکی و دندانپزشکی کاردیولوژی و پزشکی قلب و عروق
پیش نمایش صفحه اول مقاله
A common standard is inappropriate for determining the potency of ultra low molecular weight heparins such as semuloparin and bemiparin
چکیده انگلیسی

IntroductionLower low-molecular-weight heparins are being developed to improve on the safety and efficacy of antithrombotic therapy. Semuloparin and bemiparin are two depolymerized heparins produced by distinct manufacturing processes. The objective of this investigation was to determine whether a common standard could be used to define their potency.Materials and MethodsActivities were compared using typical clinical coagulation assays and pharmacological assays required for potency assessment.ResultsThe activity of semuloparin and bemiparin was comparable in FXa-based assays (anti-FXa, Heptest). However, bemiparin produced a stronger effect in the aPTT, ACT and anti-thrombin assays. Assessment of the parallelism of the concentration-response curves indicated that bemiparin and semuloparin are not equivalent in terms of anti-FIIa activity. Bemiparin had a stronger inhibitory effect on thrombin induced platelet aggregation, and a stronger interaction with HIT antibodies.ConclusionsThese data demonstrate that depolymerized heparins can exhibit a range of biologic activities making them unique agents. Pharmacopoeial parameters such as anti-IIa and anti-Xa potency and molecular weight are insufficient to characterize such agents.

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Thrombosis Research - Volume 128, Issue 4, October 2011, Pages 361-367
نویسندگان
, , , , , , , , , ,